Bruce Leuchter, CEO, Neurvati, discusses why patient engagement is essential to understanding rare diseases and driving the ...

In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts ...

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical ...

In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

In the third part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, describes ...

Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how ...

Dipanwita Das, CEO and co-founder of Sorcero, chats with Pharma Commerce to dig into the evolving drug development landscape, ...

State Medicaid leaders create a plan to ensure safety, affordability, and equitable access for children and families living with rare diseases.

When automatically moved from a zero-dollar silver plan to one that requires a premium due to plan turnover, do lower-income ...

In the second part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains ...